Loading clinical trials...
Loading clinical trials...
A Prospective, Single-arm, Multi-center Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Conditions
Interventions
the usage of Olverembatinib combined with Inotuzumab Ozogamicin
Locations
1
China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Start Date
October 30, 2022
Primary Completion Date
July 31, 2024
Completion Date
July 31, 2024
Last Updated
November 2, 2022
NCT04276870
NCT06910969
NCT04645199
NCT01499394
NCT06358430
NCT06398457
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions